Reactivity pattern of
glia-α1and glia-α2-specific-T-cell
clones to DQ2.5-glia-α1a, DQ2.5-glia-α2, 33-mer, gliadin,
and their mTG-treated forms. (A) Reactivity pattern of glia-α1-specific
T-cell clone S2 and L5107 to DQ2.5-glia-α1a and its modified
products (5 concentrations tested in each group). (B) Reactivity pattern
of glia-α2-specific T-cell clones S16 and D1 to DQ2.5-glia-α2
and its modified products (5 concentrations tested with S16 and only
the highest concentration with D1). (C) Reactivity pattern of glia-α1-specific
T-cell clones S2, and L5107 to 33-mer and its modified products (5
concentrations tested in each group). (D) Reactivity pattern of glia-α2-specific
T-cell clones S16 and D1 to 33-mer and its modified products (5 concentrations
tested with S16 and only the highest concentration with D1). (E) Reactivity
pattern of glia-α1-specific T-cell clones L6 and L10 to DQ2.5-glia-α1a,
33-mer and their modified products (only the highest concentration
tested). (F) Reactivity pattern of glia-α2-specific T-cell clones
101136 and L3-13 to DQ2.5-glia-α2, 33-mer and their modified
products (only the highest concentration tested). (G) Reactivity pattern
of glia-α1-specific T-cell clones to gliadin protein and its
modified products (only the highest concentration tested). (H) Reactivity
pattern of glia-α2-specific T-cell clones to gliadin protein
and its modified products (only the highest concentration tested).
PC, deamidated peptides as positive control; NC, native peptides as
negative control. Relative response: CPM of T cell clone caused by
peptide/that of caused by deamidated peptide (positive control).